BeiGene, Ltd.

Home » BeiGene, Ltd.

Secondary

BeiGene, Ltd.

They are a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

Symbol

BGNE

Last Closing Price
$102.49

Shares
6,300,000

Effective Date
January 18, 2018

Underwriters
Goldman Sachs, Morgan Stanley, Cowen, Leerink Partners

To view the prospectus for BeiGene, Ltd., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253